Trastuzumab deruxtecan shows 'broad activity' in HER2-expressing solid tumors

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.The HER2-directed antibody-drug conjugate, also known as T-DXd (Enhertu; AstraZeneca, Daiichi Sankyo), demonstrated the highest objective response rates and most durable

Related Keywords

Black Diamond ,Texas ,United States ,Chicago ,Illinois ,Corrs ,Tyra Biosciences ,Bydevin Mclaughlin ,Devin Mclaughlin ,Daiichi Sankyo ,Bradley Alexander Mcgregor ,University Of Texas Md Anderson Cancer Center ,Infinity Pharmaceuticals ,Menarini Group ,Debiopharm Group ,Astrazeneca ,Apeiron Biologics ,Black Diamond Therapeutics ,Karyopharm Therapeutics ,Lengo Therapeutics ,Loxo Oncology ,Oncusp Therapeutics ,Silverback Therapeutics ,Tallac Therapeutics ,Cancer Center ,Published June ,